Aurora Spine has been issued to independent U.S. patents by the U.S. Patent and Trademark Office, strengthening its intellectual property portfolio and reinforcing its innovation strategy across multiple spinal implant platforms.

The first patent (No. 12,478,411 B2) is titled “Spinal Implant for Motion Preservation or Fusion.” It represents the tenth issued U.S. patent supporting the ZIP family of products. The patented tech covers a spinal implant architecture designed to support either motion preservation or fusion, depending on clinical application.

The design leverages multiple interacting structural components that distribute load and engage progressively under physiological forces, addressing the limitations of traditional rigid implants while maintaining stability durability.

“The issuance of the tenth patent for the ZIP implant family highlights the strength, longevity, and originality of this platform,” said Trent J. Northcutt, president and CEO of Aurora Spine. “ZIP has been a foundational technology for our company, and this milestone further reinforces our ability to protect and evolve solutions that address real biomechanical and clinical challenges in spine surgery.”

The second patent issued (No. 12,478,481 B2) is titled “Bone Density Scan Result-Matched Orthopedic Implants and Methods of Use.” It protects a distinct technology focused on selecting orthopedic implants based on a patient’s bone density scan results, like DEXA measurements.

Surgeons can utilize objective bone density data to guide implant selection, as well as match implant characteristics to patient bone quality. This way, they can apply a standardized approach across varying bone density profiles.

The tech forms the bases of Aurora’s DEXA Technology platform, the company’s third bone-density-marched implant system patent.

“Bone quality is one of the most important variables in spine surgery, yet it has historically been underutilized in implant selection,” said Laszlo Garamszegi, co-founder and chief technology officer of Aurora Spine. “This patent establishes a formal, repeatable method for aligning implant selection with patient bone characteristics using objective data.”

In October, the company launched Aurora Biologics, a new division dedicated to advancing spinal fusion access through biologic innovation.